273 related articles for article (PubMed ID: 30142881)
41. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.
Zanin S; Borgo C; Girardi C; O'Brien SE; Miyata Y; Pinna LA; Donella-Deana A; Ruzzene M
PLoS One; 2012; 7(11):e49193. PubMed ID: 23145120
[TBL] [Abstract][Full Text] [Related]
42. Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.
Bruserud Ø; Reikvam H
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509370
[TBL] [Abstract][Full Text] [Related]
43. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
[TBL] [Abstract][Full Text] [Related]
44. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
45. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
[TBL] [Abstract][Full Text] [Related]
46. Casein kinase 2 inhibition impairs spontaneous and oxytocin-induced contractions in late pregnant mouse uterus.
Suhas KS; Parida S; Gokul C; Srivastava V; Prakash E; Chauhan S; Singh TU; Panigrahi M; Telang AG; Mishra SK
Exp Physiol; 2018 May; 103(5):621-628. PubMed ID: 29708304
[TBL] [Abstract][Full Text] [Related]
47. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
48. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
[TBL] [Abstract][Full Text] [Related]
49. Contribution of the CK2 Catalytic Isoforms α and α' to the Glycolytic Phenotype of Tumor Cells.
Zonta F; Borgo C; Quezada Meza CP; Masgras I; Rasola A; Salvi M; Pinna LA; Ruzzene M
Cells; 2021 Jan; 10(1):. PubMed ID: 33477590
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of Protein Kinase CK2 Prevents Adipogenic Differentiation of Mesenchymal Stem Cells Like C3H/10T1/2 Cells.
Schwind L; Schetting S; Montenarh M
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208768
[TBL] [Abstract][Full Text] [Related]
51. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
52. p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.
Schneider CC; Hessenauer A; Montenarh M; Götz C
Prostate; 2010 Feb; 70(2):126-34. PubMed ID: 19760628
[TBL] [Abstract][Full Text] [Related]
53. Sequence of CX-4945 and Cisplatin Administration Determines the Effectiveness of Drug Combination and Cellular Response in Cholangiocarcinoma Cells
Lertsuwan J; Sawasdichai A; Tasnawijitwong N; Gaston K; Jayaraman PS; Satayavivad J
Anticancer Res; 2021 Dec; 41(12):6155-6167. PubMed ID: 34848470
[TBL] [Abstract][Full Text] [Related]
54. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
[TBL] [Abstract][Full Text] [Related]
55. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
56. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
57. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
58. A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha.
Lebrin F; Chambaz EM; Bianchini L
Oncogene; 2001 Apr; 20(16):2010-22. PubMed ID: 11360185
[TBL] [Abstract][Full Text] [Related]
59. ROCK2-Specific Inhibitor KD025 Suppresses Adipocyte Differentiation by Inhibiting Casein Kinase 2.
Tran NNQ; Chun KH
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443331
[TBL] [Abstract][Full Text] [Related]
60. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
